ArticleBMC complementary medicine and therapies2025
Cicer arietinum extract as antitumor and protective agent against Ehrlich Solid Carcinoma-bearing mice.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the multitarget anticancer potential of Cochlospermum religiosum: phytochemical profiling, molecular docking, and in vitro/in vivo validation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer remains a significant global health challenge. Several plant-derived compounds have garnered the attention of cancer research for their anticancer effects. Chickpea (Cicer arietinum) is one of the top nutritious legumes with promising chemoprotective effects. We previously demonstrated that Cicer arietinum extract (CAE) has antitumor activity in vitro. Therefore, herein, we aimed to extend our findings and investigate CAE's preventive and therapeutic antitumor effects in vivo using a murine Ehrlich solid carcinoma (ESC) model.
methodsThirty-six female mice were divided into six groups: healthy controls, untreated ESC-bearing mice, CAE pre-treated groups (low, moderate, and high doses), and CAE post-treated group administered after tumor establishment. Tumor size, oxidative stress markers, antioxidant enzyme activities, and the expression of apoptotic (Casp3)- and pyroptotic (Gsdmd)-related genes were assessed. Finally, the immunohistochemical staining for the anti-apoptotic Survivin expression was assessed across different mice groups.
resultsOur data indicate that pre-treatment with moderate and high doses of CAE, as well as post-treatment, significantly inhibited tumor growth by more than 40% relative to untreated ESC-bearing controls. Histopathological analysis showed notable improvements in muscle tissue structure in CAE-treated samples. Mechanistically, CAE exerted its chemopreventive and therapeutic effects via the alleviation of oxidative stress by a significant enhancement of the antioxidant enzyme activities and increased Gpx4 mRNA expression, accompanied by a reduction of MDA and NO levels. Furthermore, CAE attenuated survivin expression, while dramatically boosting the expression of apoptotic Casp3 and pyroptotic Gsdmd markers, particularly in the post-treatment group.
conclusionThese findings suggest that CAE is a promising anticancer agent with protective effects against ESC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.